Liquidia (LQDA) Operating Income Growth (1y) (2021 - 2026)
Liquidia (LQDA) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.38 Bn | 6.10 Bn | 160.92 Mn | 328.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 328.01% |
| Mar 31, 2026 | 273.62% |
| Dec 31, 2025 | 154.80% |
| Sep 30, 2025 | 106.05% |
| Jun 30, 2025 | -37.90% |
| Mar 31, 2025 | -23.00% |
| Dec 31, 2024 | -36.58% |
| Sep 30, 2024 | -96.02% |
| Jun 30, 2024 | -19.15% |
| Mar 31, 2024 | -211.97% |
| Dec 31, 2023 | -306.90% |
| Sep 30, 2023 | -68.62% |
| Jun 30, 2023 | -154.46% |
| Mar 31, 2023 | 36.21% |
| Dec 31, 2022 | 42.82% |
| Sep 30, 2022 | -24.73% |
| Jun 30, 2022 | -41.17% |
| Mar 31, 2022 | -60.78% |
| Dec 31, 2021 | 28.60% |
| Sep 30, 2021 | 52.20% |